| On December 7, 2022, the Centers for Medicare & Medicaid Services (CMS) will convene a panel of the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC). National Coverage Determinations (NCDs) resulting in Coverage with Evidence Development (CED) can expedite earlier Medicare beneficiary access to innovative technology while developing evidence and ensuring that systematic patient safeguards are in place to reduce the risks inherent to new technologies, or to new applications of older technologies. This MEDCAC meeting will examine the minimum CED criteria for clinical studies submitted for CMS approval. The AHRQ Analysis of Requirements for Coverage with Evidence Development (CED) draft report, was released on September 7, 2022 and is open for public comment until September 28, 2022. The report and link to submit a public comment may be found at https://effectivehealthcare.ahrq.gov/products/coverage-evidence-development/draft-comment. The AHRQ report will be discussed during the December 7, 2022 MEDCAC. | 